Evidence Snapshot

Receptor-type tyrosine-protein kinase FLT3

CHEMBL1974 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:07:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:07 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1974

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor-type tyrosine-protein kinase FLT3 as ChEMBL target CHEMBL1974, mapped to UniProt P36888. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Receptor-type tyrosine-protein kinase FLT3

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1974

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P36888

Receptor-type tyrosine-protein kinase FLT3

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Receptor-type tyrosine-protein kinase FLT3 matters

As of 2026-09-13

Receptor-type tyrosine-protein kinase FLT3 is reviewed as Receptor-type tyrosine-protein kinase FLT3 (UniProt P36888); Receptor-type tyrosine-protein kinase FLT3 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.; 22 linked drugs keep this evidence frame grounded.; the current evidence base includes 57 approved drugs, 8543 compounds, and 2902 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Receptor-type tyrosine-protein kinase FLT3

Receptor-type tyrosine-protein kinase FLT3 Sequence length is 993 aa.

Review this target as Receptor-type tyrosine-protein kinase FLT3, mapped to UniProt P36888. Sequence length is 993 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P36888 Protein

Disease context

acute myeloid leukemia

Receptor-type tyrosine-protein kinase FLT3 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 22 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include 4SC-203, AKN-028, AMG553.

Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include 4SC-203, AKN-028, AMG553, CRENOLANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 22 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 57 approved drugs, 8543 compounds, and 2902 assays for this target. The dominant activity type is IC50. CHEMBL5176837 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5176837 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

57 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Receptor-type tyrosine-protein kinase FLT3 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P36888, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acute myeloid leukemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8543

Total Compounds

2902

Total Assays

Approved Drugs

IC50: 7094.0, KI: 1139.0, EC50: 46.0, KD: 1596.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5176837	11.0	Kd	—
No preferred name CHEMBL5927784	11.0	Kd	—
No preferred name CHEMBL4744130	10.8	IC50	—
No preferred name CHEMBL5195819	10.8	Kd	—
No preferred name CHEMBL2105728	10.8	Kd	Clinical

Approved Drugs

Structure	Compound	First Approval
	QUIZARTINIB CHEMBL576982	2023
	QUIZARTINIB DIHYDROCHLORIDE CHEMBL2105709	2023
	PACRITINIB CHEMBL2035187	2022
	PRALSETINIB CHEMBL4582651	2020
	FILGOTINIB CHEMBL3301607	2020
	FEDRATINIB CHEMBL1287853	2019
	PEXIDARTINIB CHEMBL3813873	2019
	ENTRECTINIB CHEMBL1983268	2019
	FOSTAMATINIB CHEMBL2103830	2018
	GILTERITINIB CHEMBL3301622	2018
	MIDOSTAURIN CHEMBL608533	2017
	TIVOZANIB CHEMBL1289494	2017
	ABEMACICLIB CHEMBL3301610	2017
	BRIGATINIB CHEMBL3545311	2017
	CERITINIB CHEMBL2403108	2014
	NINTEDANIB CHEMBL502835	2014
	IBRUTINIB CHEMBL1873475	2013
	REGORAFENIB CHEMBL1946170	2012
	PONATINIB CHEMBL1171837	2012
	AXITINIB CHEMBL1289926	2012
	BOSUTINIB CHEMBL288441	2012
	CABOZANTINIB CHEMBL2105717	2012
	VANDETANIB CHEMBL24828	2011
	CRIZOTINIB CHEMBL601719	2011
	PAZOPANIB CHEMBL477772	2009
	SUNITINIB CHEMBL535	2006
	SORAFENIB CHEMBL1336	2005
	ERLOTINIB CHEMBL553	2004
	GEFITINIB CHEMBL939	2003
	IMATINIB CHEMBL941	2001

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:07:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:07 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1974